Twist Bioscience (NASDAQ:TWST) CFO Adam Laponis Sells 5,517 Shares

Twist Bioscience Corporation (NASDAQ:TWST) CFO Adam Laponis sold 5,517 shares of the business’s stock in a transaction on Thursday, October 30th. The shares were sold at an average price of $31.44, for a total transaction of $173,454.48. Following the completion of the sale, the chief financial officer owned 111,008 shares in the company, valued at $3,490,091.52. This represents a 4.73% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Adam Laponis also recently made the following trade(s):

• On Thursday, October 9th, Adam Laponis sold 2,517 shares of Twist Bioscience stock. The stock was sold at an average price of $32.92, for a total value of $82,859.64.
• On Wednesday, October 8th, Adam Laponis sold 3,000 shares of Twist Bioscience stock. The stock was sold at an average price of $31.15, for a total value of $93,450.00.
• On Monday, October 6th, Adam Laponis sold 5,875 shares of Twist Bioscience stock. The stock was sold at an average price of $32.19, for a total value of $189,116.25.

Twist Bioscience Trading Down 4.0%

Shares of TWST traded down $1.32 during trading hours on Monday, hitting $31.57. 1,224,978 shares of the stock traded hands, compared to its average volume of 1,305,728. The company has a current ratio of 3.90, a quick ratio of 3.60 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a 1-year low of $24.07 and a 1-year high of $55.33. The firm has a market capitalization of $1.91 billion, a PE ratio of -21.77 and a beta of 2.38. The business has a fifty day moving average of $28.97 and a 200-day moving average of $31.82.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Monday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.07. Twist Bioscience had a negative net margin of 23.51% and a negative return on equity of 29.03%. The company had revenue of $96.06 million for the quarter, compared to the consensus estimate of $95.52 million. Analysts expect that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Institutional Investors Weigh In On Twist Bioscience

A number of hedge funds and other institutional investors have recently made changes to their positions in TWST. GAMMA Investing LLC raised its stake in shares of Twist Bioscience by 68.1% in the 1st quarter. GAMMA Investing LLC now owns 748 shares of the company’s stock valued at $29,000 after purchasing an additional 303 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Twist Bioscience by 15.0% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company’s stock valued at $85,000 after purchasing an additional 302 shares during the last quarter. Geneos Wealth Management Inc. acquired a new stake in shares of Twist Bioscience in the second quarter valued at approximately $97,000. CWM LLC raised its holdings in shares of Twist Bioscience by 61.4% in the third quarter. CWM LLC now owns 4,331 shares of the company’s stock valued at $122,000 after purchasing an additional 1,648 shares during the last quarter. Finally, Bayforest Capital Ltd increased its stake in Twist Bioscience by 49.3% in the 1st quarter. Bayforest Capital Ltd now owns 4,860 shares of the company’s stock valued at $191,000 after buying an additional 1,604 shares during the last quarter.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Evercore ISI cut their price objective on shares of Twist Bioscience from $46.00 to $42.00 and set an “outperform” rating on the stock in a report on Tuesday, October 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Twist Bioscience in a research note on Wednesday, October 8th. Barclays cut their target price on Twist Bioscience from $45.00 to $40.00 and set an “overweight” rating on the stock in a research note on Thursday, October 2nd. Finally, Cowen reiterated a “buy” rating on shares of Twist Bioscience in a research report on Monday, August 4th. Nine equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $48.56.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.